Your browser doesn't support javascript.
loading
Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial.
Ishola, David; Manno, Daniela; Afolabi, Muhammed O; Keshinro, Babajide; Bockstal, Viki; Rogers, Baimba; Owusu-Kyei, Kwabena; Serry-Bangura, Alimamy; Swaray, Ibrahim; Lowe, Brett; Kowuor, Dickens; Baiden, Frank; Mooney, Thomas; Smout, Elizabeth; Köhn, Brian; Otieno, Godfrey T; Jusu, Morrison; Foster, Julie; Samai, Mohamed; Deen, Gibrilla Fadlu; Larson, Heidi; Lees, Shelley; Goldstein, Neil; Gallagher, Katherine E; Gaddah, Auguste; Heerwegh, Dirk; Callendret, Benoit; Luhn, Kerstin; Robinson, Cynthia; Leyssen, Maarten; Greenwood, Brian; Douoguih, Macaya; Leigh, Bailah; Watson-Jones, Deborah.
Affiliation
  • Ishola D; London School of Hygiene & Tropical Medicine, London, UK; EBOVAC Project, Kambia, Kambia district, Sierra Leone.
  • Manno D; London School of Hygiene & Tropical Medicine, London, UK. Electronic address: daniela.manno@lshtm.ac.uk.
  • Afolabi MO; London School of Hygiene & Tropical Medicine, London, UK; EBOVAC Project, Kambia, Kambia district, Sierra Leone.
  • Keshinro B; Janssen Vaccines and Prevention BV, Leiden, Netherlands.
  • Bockstal V; Janssen Vaccines and Prevention BV, Leiden, Netherlands.
  • Rogers B; EBOVAC Project, Kambia, Kambia district, Sierra Leone; College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown, Sierra Leone.
  • Owusu-Kyei K; London School of Hygiene & Tropical Medicine, London, UK; EBOVAC Project, Kambia, Kambia district, Sierra Leone.
  • Serry-Bangura A; EBOVAC Project, Kambia, Kambia district, Sierra Leone; College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown, Sierra Leone.
  • Swaray I; EBOVAC Project, Kambia, Kambia district, Sierra Leone; College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown, Sierra Leone.
  • Lowe B; London School of Hygiene & Tropical Medicine, London, UK; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya; Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK.
  • Kowuor D; London School of Hygiene & Tropical Medicine, London, UK; EBOVAC Project, Kambia, Kambia district, Sierra Leone.
  • Baiden F; London School of Hygiene & Tropical Medicine, London, UK; EBOVAC Project, Kambia, Kambia district, Sierra Leone.
  • Mooney T; London School of Hygiene & Tropical Medicine, London, UK; EBOVAC Project, Kambia, Kambia district, Sierra Leone.
  • Smout E; London School of Hygiene & Tropical Medicine, London, UK; EBOVAC Project, Kambia, Kambia district, Sierra Leone.
  • Köhn B; London School of Hygiene & Tropical Medicine, London, UK; EBOVAC Project, Kambia, Kambia district, Sierra Leone.
  • Otieno GT; London School of Hygiene & Tropical Medicine, London, UK; EBOVAC Project, Kambia, Kambia district, Sierra Leone.
  • Jusu M; London School of Hygiene & Tropical Medicine, London, UK; EBOVAC Project, Kambia, Kambia district, Sierra Leone; College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown, Sierra Leone.
  • Foster J; London School of Hygiene & Tropical Medicine, London, UK.
  • Samai M; College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown, Sierra Leone.
  • Deen GF; College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown, Sierra Leone.
  • Larson H; London School of Hygiene & Tropical Medicine, London, UK; Department of Health Metrics Sciences, University of Washington, Seattle, WA, USA.
  • Lees S; London School of Hygiene & Tropical Medicine, London, UK.
  • Goldstein N; Janssen Vaccines and Prevention BV, Leiden, Netherlands.
  • Gallagher KE; London School of Hygiene & Tropical Medicine, London, UK.
  • Gaddah A; Janssen Research & Development, Beerse, Belgium.
  • Heerwegh D; Janssen Research & Development, Beerse, Belgium.
  • Callendret B; Janssen Vaccines and Prevention BV, Leiden, Netherlands.
  • Luhn K; Janssen Vaccines and Prevention BV, Leiden, Netherlands.
  • Robinson C; Janssen Vaccines and Prevention BV, Leiden, Netherlands.
  • Leyssen M; Janssen Vaccines and Prevention BV, Leiden, Netherlands.
  • Greenwood B; London School of Hygiene & Tropical Medicine, London, UK.
  • Douoguih M; Janssen Vaccines and Prevention BV, Leiden, Netherlands.
  • Leigh B; College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown, Sierra Leone.
  • Watson-Jones D; London School of Hygiene & Tropical Medicine, London, UK; Mwanza Intervention Trials Unit, National Institute for Medical Research, Mwanza, Tanzania.
Lancet Infect Dis ; 22(1): 97-109, 2022 01.
Article in En | MEDLINE | ID: mdl-34529963
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Viral Vaccines / Hemorrhagic Fever, Ebola / Vaccines, DNA / Ebola Vaccines / Ebolavirus / Immunogenicity, Vaccine / Antibodies, Viral Type of study: Clinical_trials / Guideline Limits: Adult / Female / Humans / Male Country/Region as subject: Africa Language: En Journal: Lancet Infect Dis Journal subject: DOENCAS TRANSMISSIVEIS Year: 2022 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Viral Vaccines / Hemorrhagic Fever, Ebola / Vaccines, DNA / Ebola Vaccines / Ebolavirus / Immunogenicity, Vaccine / Antibodies, Viral Type of study: Clinical_trials / Guideline Limits: Adult / Female / Humans / Male Country/Region as subject: Africa Language: En Journal: Lancet Infect Dis Journal subject: DOENCAS TRANSMISSIVEIS Year: 2022 Document type: Article Affiliation country: Country of publication: